UBS starts Regeneron at Buy, arguing the Street is undervaluing Dupixent's future. That is a call on the out-year franchise, not the current quarter, so the tape question is whether funds actually re-

UBS initiates Regeneron as Buy, citing Street undervaluation of Dupixent's future.